INS and type 1 diabetes mellitus: It is estimated that by 2050, there will be 1.31 billion people living with diabetes globally.405 MSCs are emerging as promising therapeutic options for diabetes,406 particularly for diabetes types 1 and 2, where immune destruction of insulin-producing beta cells in the pancreas leads to absolute or relative insulin deficiency.